Literature DB >> 27471609

Tumor relapse prevented by combining adoptive T cell therapy with Salmonella typhimurium.

David C Binder1, Ainhoa Arina2, Frank Wen3, Tony Tu2, Ming Zhao4, Robert M Hoffman5, Derek A Wainwright6, Hans Schreiber7.   

Abstract

We recently reported that therapeutic vaccination with live tumor antigen-producing Salmonella typhimurium rescues dysfunctional endogenous T cell responses and eradicates long-established tumors refractory to αCTLA-4 and αPD-L1 checkpoint inhibitor blockade. Here, we show that live intravenously injected or heat-killed (HK) intratumorally injected Salmonella typhimurium, even when not producing tumor antigen, synergize with adoptive T cell therapy to eradicate tumors. These data demonstrate that the combination of adoptive T cell transfer with the injection of live or dead Salmonella typhimurium is a promising approach for cancer treatment.

Entities:  

Keywords:  Adoptive T cell therapy; bacteria; macrophage; relapse; tumor stroma

Year:  2016        PMID: 27471609      PMCID: PMC4938310          DOI: 10.1080/2162402X.2015.1130207

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  32 in total

1.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

2.  Progression of cancer from indolent to aggressive despite antigen retention and increased expression of interferon-gamma inducible genes.

Authors:  Terry H Wu; Karin Schreiber; Ainhoa Arina; Nikolai N Khodarev; Elena V Efimova; Donald A Rowley; Ralph R Weichselbaum; Hans Schreiber
Journal:  Cancer Immun       Date:  2011-06-30

3.  Containment of tumor-colonizing bacteria by host neutrophils.

Authors:  Kathrin Westphal; Sara Leschner; Jadwiga Jablonska; Holger Loessner; Siegfried Weiss
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

4.  Current concepts in the diagnosis and management of cytokine release syndrome.

Authors:  Daniel W Lee; Rebecca Gardner; David L Porter; Chrystal U Louis; Nabil Ahmed; Michael Jensen; Stephan A Grupp; Crystal L Mackall
Journal:  Blood       Date:  2014-05-29       Impact factor: 22.113

5.  IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers.

Authors:  Bin Zhang; Theodore Karrison; Donald A Rowley; Hans Schreiber
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

6.  Bystander elimination of antigen loss variants in established tumors.

Authors:  Michael T Spiotto; Donald A Rowley; Hans Schreiber
Journal:  Nat Med       Date:  2004-02-22       Impact factor: 53.440

7.  A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growth.

Authors:  Frank T Wen; Ronald A Thisted; Donald A Rowley; Hans Schreiber
Journal:  Oncoimmunology       Date:  2012-03-01       Impact factor: 8.110

8.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

9.  Image-guided drug delivery: preclinical applications and clinical translation.

Authors:  Tarun Ojha; Larissa Rizzo; Gert Storm; Fabian Kiessling; Twan Lammers
Journal:  Expert Opin Drug Deliv       Date:  2015-06-17       Impact factor: 6.648

Review 10.  Tumour heterogeneity and cancer cell plasticity.

Authors:  Corbin E Meacham; Sean J Morrison
Journal:  Nature       Date:  2013-09-19       Impact factor: 49.962

View more
  6 in total

1.  The Boosting Potential of Bacteria in Cancer Immunotherapy.

Authors:  David C Binder; Derek A Wainwright
Journal:  Trends Mol Med       Date:  2017-06-02       Impact factor: 11.951

Review 2.  Tumour-targeting bacteria-based cancer therapies for increased specificity and improved outcome.

Authors:  Sebastian Felgner; Vinay Pawar; Dino Kocijancic; Marc Erhardt; Siegfried Weiss
Journal:  Microb Biotechnol       Date:  2017-08-03       Impact factor: 5.813

3.  Local application of bacteria improves safety of Salmonella -mediated tumor therapy and retains advantages of systemic infection.

Authors:  Dino Kocijancic; Sebastian Felgner; Tim Schauer; Michael Frahm; Ulrike Heise; Kurt Zimmermann; Marc Erhardt; Siegfried Weiss
Journal:  Oncotarget       Date:  2017-07-25

Review 4.  Perspectives on Oncolytic Salmonella in Cancer Immunotherapy-A Promising Strategy.

Authors:  Ding Wang; Xiaodong Wei; Dhan V Kalvakolanu; Baofeng Guo; Ling Zhang
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

Review 5.  Recombinant Attenuated Salmonella enterica as a Delivery System of Heterologous Molecules in Cancer Therapy.

Authors:  Elayne Irene Becerra-Báez; Sergio Enrique Meza-Toledo; Paola Muñoz-López; Luis Fernando Flores-Martínez; Karla Fraga-Pérez; Kevin Jorge Magaño-Bocanegra; Uriel Juárez-Hernández; Armando Alfredo Mateos-Chávez; Rosendo Luria-Pérez
Journal:  Cancers (Basel)       Date:  2022-08-30       Impact factor: 6.575

Review 6.  Salmonella-Based Targeted Cancer Therapy: Updates on A Promising and Innovative Tumor Immunotherapeutic Strategy.

Authors:  Christian Ronquillo Pangilinan; Che-Hsin Lee
Journal:  Biomedicines       Date:  2019-05-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.